Placeholder Banner

CSBA Comments to Centers for Medicare & Medicaid Services (CMS) on Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026

April 14, 2023

The CSBA Board of Directors endorses BIO’s formal comments on
the Medicare Drug Price Negotiation Program, which are appended to this letter.

 

Download Full Comments Below
CSBA Final to CMS with BIO Letter
Discover More
The Council of State Bioscience Associations wrote House and Senate leaders to urge support of H.R. 5539 and S. 3131, the Optimizing Research Progress Hope and New Cures Act.